. 2019 Feb 6;21:21. doi: 10.1186/s13058-019-1109-0

Table 2.

Association between EmiR expression at Ext2 and clinicopathological characteristics in LBC patients

			Ext2
			EmiR-21		EmiR-222		EmiR-221		EmiR-105		EmiR-155
		n	Median	p value	Median	p value	Median	p value	Median	p value	Median	p value
Age (years)	< 50	19	3.975	0.585	1.851	0.536	1.705	0.771	2.534	0.166	2.173	0.536
Age (years)	≥ 50	14	3.033	0.585	2.100	0.536	1.718	0.771	11.182	0.166	1.401	0.536
Menopause	Pre	20	4.159	0.094	2.250	0.461	1.890	0.338	3.916	0.224	2.177	0.768
Menopause	Post	13	2.192	0.094	1.551	0.461	1.422	0.338	10.603	0.224	1.507	0.768
T	T1–T2	18	3.668	0.233	2.382	0.828	2.238	0.219	16.929	0.112	2.601	0.159
T	T3–T4	15	3.246	0.233	1.851	0.828	1.286	0.219	3.484	0.112	1.819	0.159
N	0	11	3.975	0.621	3.037	0.621	2.490	0.006*	21.588	0.445	1.344	0.928
N	1–3	18	3.477	0.621	2.250	0.621	1.095	0.006*	8.885	0.445	2.177	0.928
Estrogen receptor	Negative	8	2.133	0.450	1.213	0.475	1.095	0.585	5.405	0.529	0.839	0.120
Estrogen receptor	Positive	25	3.933	0.450	2.649	0.475	2.000	0.585	11.760	0.529	2.173	0.120
Progesterone receptor	Negative	11	2.192	0.541	1.338	0.760	1.787	0.541	7.327	0.789	3.224	0.849
Progesterone receptor	Positive	22	3.668	0.541	2.250	0.760	1.686	0.541	8.528	0.789	1.899	0.849
HER2	Negative	27	3.933	0.031*	3.037	0.056	1.705	0.744	5.297	0.484	2.173	0.161
HER2	Positive	6	0.857	0.031*	0.536	0.056	41.874	0.744	46.810	0.484	0.639	0.161
KI67	< 20%	6	4.996	0.427	1.464	0.283	0.321	0.176	3.691	0.963	1.355	0.191
KI67	≥ 20	27	3.246	0.427	3.037	0.283	1.787	0.176	10.444	0.963	3.201	0.191
Perou’s classification	Basal-like	5	2.192	0.655	1.338	0.666	1.286	0.666	3.484	0.510	0.983	0.232
	Luminal A	5	6.058		0.729		0.334		2.085		1.367
	Luminal B	20	3.324		3.052		2.038		16.580		3.459
	HER2neu	3	2.074		0.175		0.307		10.603		0.695

Wilcoxon signed-rank test and Kruskal-Wallis test were used. Abbreviations: CTCs circulating tumor cells, Ext2 extraction during neoadjuvant treatment, T tumor size, N lymph node status. *p > 0.05